TABLE 2.

Baseline characteristics, plasma lipid and Lp(a) levels, and predominant apo(a) isoform size in subjects who developed CHD during a mean follow-up of 12.3 years, and in subjects free of CHD

	Men			Women
Variable	Controls n = 1,230	CHD cases n = 98	P	Controls n = 1,505	CHD cases n = 47	P
Age, y	55 ± 10	59 ± 10	<0.0001	54 ± 10	61 ± 9	<0.0001
BMI, kg/m2	28.17 ± 4.25	28.93 ± 3.49	0.046	26.74 ± 5.41	28.27 ± 5.66	0.057
TC, mg/dl	201 ± 33	207 ± 39	0.117	208 ± 37	232 ± 37	<0.0001
TG, mg/dl	128 [88, 192]	149 [104, 207]	0.011a	112 [81, 162]	172 [106, 223]	<0.0001a
LDL-C, mg/dlb	121 ± 30	124 ± 34	0.457	118 ± 33	141 ± 31	<0.0001
HDL-C, mg/dl	43 ± 11	41 ± 10	0.064	56 ± 16	47 ± 12	<0.0001
Lp(a) protein, nmol/L [NWRL]	18.1 [4.4, 65]	36.3 [10.6, 124.4]	0.003a	20.6 [5.6, 71.3]	18.8 [4.4, 53.1]	0.353a
Lp(a), mg/dl [Wako]c	10.8 [4.9, 30]	20.6 [7.6, 38]	0.010a	13 [5.9, 34]	12 [5.5, 56]	0.71a
Lp(a)-C, mg/dl [Genzyme]d	4.9 [2.6, 9.5]	5.9 [3.2, 11.6]	0.045a	4.7 [2.5, 9.3]	5.5 [2.6, 12.2]	0.49a
Predominant isoform	24.0 ± 5.5	22.7 ± 5.5	0.025	23.9 ± 5.6	25.6 ± 6.2	0.044
Systolic blood pressure, mm Hg	129 ± 17	134 ± 18	0.006	124 ± 20	138 ± 21	<0.0001
Diastolic blood pressure, mm Hg	77 ± 10	77 ± 10	0.689	73 ± 10	77 ± 9	0.003
Hypertension, %	34	55	<0.0001	29	62	<.0001
Smoking, %	19	24	0.307	19	37	0.003
Diabetes, %	8	18	0.001	5	17	0.0002
Lipid-lowering medications, %	7	19	<0.0001	5	13	0.030
Postmenopausal, %				65	89	0.0005
Hormone therapy, %				17	13	0.436

Data shown as mean ± SD, with the exception of TG and Lp(a), where values are shown as median [IQR]. HDL-C, HDL-cholesterol; LDL-C, LDL cholesterol.

^aP value after variable was log-transformed.

^bLDL-C concentration obtained after the subtraction of Lp(a) cholesterol.

^cWako method: men, 1,045 controls and 86 cases; women, 1,300 controls and 41 cases.

^dGenzyme method: men, 1,131 controls and 94 cases; women, 1,376 controls and 44 cases.